SD-101 dermal cream (6%)
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermolysis Bullosa
Conditions
Epidermolysis Bullosa
Trial Timeline
Mar 26, 2014 → Sep 14, 2018
NCT ID
NCT02090283About SD-101 dermal cream (6%)
SD-101 dermal cream (6%) is a phase 2 stage product being developed by Amicus Therapeutics for Epidermolysis Bullosa. The current trial status is terminated. This product is registered under clinical trial identifier NCT02090283. Target conditions include Epidermolysis Bullosa.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02090283 | Phase 2 | Terminated |
Competing Products
13 competing products in Epidermolysis Bullosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efgartigimod | Argenx | Phase 1/2 | 38 |
| KB803 + Placebo | Krystal Biotech | Phase 3 | 74 |
| Topical beremagene geperpavec + Placebo gel | Krystal Biotech | Phase 1/2 | 38 |
| Topical Beremagene Geperpavec | Krystal Biotech | Phase 3 | 74 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech | Phase 3 | 74 |
| SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%) | Amicus Therapeutics | Phase 2 | 49 |
| SD-101-6.0 cream + Placebo (SD-101-0.0) cream | Amicus Therapeutics | Phase 3 | 74 |
| SD-101-6.0 cream | Amicus Therapeutics | Phase 3 | 74 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Abeona Therapeutics | Phase 1/2 | 33 |
| EB-101 | Abeona Therapeutics | Phase 3 | 69 |
| EB-101 Surgical application of RDEB wounds | Abeona Therapeutics | Phase 3 | 69 |
| VPD-737 | Vyne Therapeutics | Phase 2 | 44 |
| Serlopitant Tablet + Placebo Oral Tablet | Vyne Therapeutics | Phase 2 | 44 |